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Intra-articular interleukin-1 receptor
antagonist (IL1-ra) microspheres for
posttraumatic osteoarthritis: in vitro
biological activity and in vivo disease
modifying effect
Khaled A. Elsaid1,2*, Anand Ubhe1, Ziyad Shaman1 and Gerard D’Souza1
Abstract
Background: Interleukin-1 receptor antagonist (IL-1 ra) can be disease-modifying in posttraumatic osteoarthritis (PTOA).
One limitation is its short joint residence time. We hypothesized that IL-1 ra encapsulation in poly (lactide-co-glycolide)
(PLGA) microspheres reduces IL-1 ra systemic absorption and provides an enhanced anti-PTOA effect.
Methods: IL-1 ra release kinetics and biological activity: IL-1 ra encapsulation into PLGA microsphere was performed using
double emulsion solvent extraction. Lyophilized PLGA IL-1 ra microspheres were resuspended in PBS and supernatant
IL-1 ra concentrations were assayed. The biological activity of IL-1 ra from PLGA IL-1 ra microspheres was performed
using IL-1 induced lymphocyte proliferation and bovine articular cartilage degradation assays. Systemic absorption of IL-1
ra following intra-articular (IA) injection of PLGA IL-1 ra or IL-1 ra: At 1, 3, 6, 12 and 24 h following injection of 50 μl PLGA
IL-1 ra (n = 6) or IL-1 ra (n = 6), serum samples were collected and IL-1 ra concentrations were determined. Anterior
cruciate ligament transection (ACLT) and IA dosing: ACLT was performed in 8–10 week old male Lewis rats (n = 42). PBS
(50 μl; n = 9), IL-1 ra (50 μl; 5 mg/ml; n = 13), PLGA IL-1 ra (50 μl; equivalent to 5 mg/ml IL-1 ra; n = 14) or PLGA particles
(50 μl; n = 6) treatments were performed on days 7, 14, 21 and 28 following ACLT. Cartilage and synovial histopathology:
On day 35, animal ACLT joints were harvested and tibial cartilage and synovial histopathology scoring was performed.
Results: Percent IL-1 ra content in the supernatant at 6 h was 13.44 ± 9.27 % compared to 34.16 ± 12.04 %, 47.89 ± 12.
71 %, 57.14 ± 11.71 %, and 93.90 ± 8.50 % at 12, 24, 48 and 72 h, respectively. PLGA IL-1 ra inhibited lymphocyte
proliferation and cartilage degradation similar to IL-1 ra. Serum IL-1 ra levels were significantly lower at 1, 3, and 6 h
following PLGA IL-1 ra injection compared to IL-1 ra. Cartilage and synovial histopathology scores were significantly
lower in the PLGA IL-1 ra group compared to PBS and PLGA groups (p < 0.001).
Conclusions: IL-1 ra encapsulation in PLGA microspheres is feasible with no alteration to IL-1 ra biological activity.
PLGA IL-1 ra exhibited an enhanced disease-modifying effect in a PTOA model compared to similarly dosed IL-1 ra.
Keywords: Interleukin-1 receptor antagonist, Posttraumatic osteoarthritis, IL1 ra microspheres, Bioactivity of IL1ra
Abbrevations: ACL, Anterior cruciate ligament; ACLT, Anterior cruciate ligament transection; IL-1 ra, Interleukin-1 receptor
antagonist; IL-1, Interleukin-1; IL-6, Interleukin-6; N, Normal; NaOH, Sodium hydroxide; PLGA, Poly (lactide-co-glycolide);
PTOA, Posttraumatic osteoarthritis; SDS, Sodium dodecyl sulfate; TNFα, Tumor necrosis factor alpha
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Background
Posttraumatic osteoarthritis (PTOA) is estimated to affect
approximately 5.6 million individuals in the US with an-
terior cruciate ligament (ACL) ruptures accounting for a
considerable proportion of PTOA disease burden. Factors
e.g. direct cartilage injury; inflammation and joint instabil-
ity converge to trigger early cartilage degeneration. Proin-
flammatory cytokines e.g. interleukin-1 (IL1), IL6, and
tumor necrosis factor alpha (TNFα) are elevated in syn-
ovial fluid aspirates from patients following ACL injury
and play an important role in the initial disease process
(Cameron et al. 1994; Catterall et al. 2010; Elsaid et al.
2008; Higuchi et al. 2006; Irie et al. 2003). Interleukin-1
receptor antagonist (IL-1 ra) is a promising treatment that
has shown a disease-modifying activity in pre-clinical ani-
mal PTOA models (Allen et al. 2011; Caron et al. 1996).
Clinically, biologic IL-1 inhibitor therapies have failed to
show a sustained clinical effect contributed by a short
joint residence time following intra-articular administra-
tion (Chevalier et al. 2009; Cohen et al. 2011).
The joint residence time of small molecules and large
polymers following intra-articular administration is in
the order of hours (Owen et al. 1994; Vugmeyster et al.
2012). Encapsulation of therapeutic agents in pharma-
ceutical carriers increases joint residence time and en-
hances the pharmacologic activity of these agents
(Pradal et al. 2015; Vanniasinghe et al. 2014; Evans et al.
2014). Poly (lactide-co-glycolide) (PLGA) is an inert bio-
degradable polymer that has been successfully used to
encapsulate small molecules, nucleic acids and large re-
combinant proteins (Gaignaux et al. 2012; Jilek et al.
2005; Wang et al. 2012; Wischke & Schwendeman 2008;
Nie et al. 2015). Specifically, PLGA encapsulation was
used to provide sustained release of non-steroidal anti-
inflammatory drugs, chondroitin sulfate and anti-TNFα
therapies in pre-clinical arthritis models (Higaki et al.
2005; Jiang et al. 2011; Présumey et al. 2012).
In this study, we explored the feasibility of encapsulat-
ing IL-1 ra in PLGA and we studied the biological activ-
ity of IL-1 ra released from PLGA IL-1 ra microspheres.
Furthermore, we studied the disease-modifying effect of
PLGA IL-1 ra microspheres in a PTOA rat model of
ACL transection.
Methods
Preparation and characterization of IL-1 ra microspheres
Anakinra (Kineret), a 100 mg per 0.67 ml pre-filled syringe
for subcutaneous administration, is the form of IL-1 ra
used in this study. IL-1 ra microspheres were prepared by
a double emulsion solvent extraction method as previ-
ously described (Butoescu et al. 2008). IL-1 ra (5 mg;
33 μl) and 3 mg/100 μl of iron oxide dispersion were
mixed together and bath sonicated for 30 s to get a uni-
form dispersion. This aqueous phase was emulsified with
1 ml of 100 mg/ml solution of PLGA: lactide: glycolide
85:15, MW 50,000–75,000 (Sigma Aldrich, USA) in ethyl
acetate. The resultant emulsion was then dispersed in
2 ml of 2 % polyvinyl alcohol (PVA) solution in distilled
water by probe sonication for 15 s. This double emulsion
was diluted with 10 ml of 0.3 % PVA solution in distilled
water and stirred mechanically for 4 h to yield the parti-
cles. The resultant particles were magnetically separated
and washed with distilled water and the lyophilized. Ly-
ophilized particles were stored at 4 °C and were reconsti-
tuted as needed in PBS. Particle size distribution and
surface charge were analyzed using 90 Plus particle size
analyzer (Brookhaven Instrument Corporation, USA).
Representative preparations were imaged using a scanning
electron microscope. The incorporation efficiency of IL-1
ra in PLGA microparticles was determined using lyophi-
lized PLGA IL-1 ra from 4 different preparations. A total
of 1 mg of PLGA IL-1 ra microparticles was reconstituted
in 1 ml of 5 % SDS in 0.1 N NaOH and incubated for 15 h
at room temperature, where by all powder dissolved. Total
protein content was determined using the BCA colorimet-
ric assay (ThermoFisher Scientific, USA) and empty
PLGA particles were processed in a similar manner and
used as a blank. IL-1 ra incorporation was expressed as a
ratio of the total measured protein in microparticles to the
total protein used in the formulation process. The data
represents the average IL-1 ra percent incorporation from
the 4 preparations. The release of IL-1 ra from the PLGA
micrsopheres was evaluated using the equivalent of 5 mg
of PLGA IL-1 ra from 4 different preparations following
reconstitution in 1 ml of PBS and incubation at room
temperature with shaking. At 6, 12, 24, 48 and 72 h
following reconstitution, particles were centrifuged at
10,000 rpm and the supernatant was sampled. The IL-1 ra
concentration in the supernatant was quantified using a
commercially available ELISA (R&D Systems, USA) and
was expressed as the ratio of IL-1 ra content in the super-
natant to the total expected amount of incorporated IL-1
ra. Data represents the average IL-1 ra percent release
from the 4 preparations.
Biological activity of IL-1 ra released from PLGA IL-1 ra
microspheres using human lymphocyte proliferation
assay
We have utilized RPMI 1788 human lymphocytes
(American Type Cell Culture, USA) to evaluate the
dose-dependent proliferation-inhibitory effect of IL-1 ra
released from PLGA IL-1 ra microspheres (Shamji et al.
2007; Vandenabeele et al. 1990). RPMI 1788 cells were
grown in RPMI 1640 culture medium (Sigma Aldrich,
USA) supplemented with 10 % fetal bovine serum,
2 mM L-glutamine, 0.05 mM β mercaptoethanol, 1 mM
sodium pyruvate, 10 mM HEPES and 1 % penicillin/
streptomycin. Using sterile 96-well plates (Corning,
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USA), a total of 1,000 cells in 80 μl media was added to
each well followed by the addition of recombinant hu-
man IL1β (R&D Systems) at a final concentration of
500 pg/ml with or without the addition of iron-oxide
containing PLGA, IL-1 ra or PLGA IL-1 ra (pooled from
4 different preparations) at a final concentration of 1 ng/
ml or 25 ng/ml. The final volume in each well was
100 μl. RPMI cells that received no IL1β, PLGA IL-1 ra
or IL-1 ra served as controls. Plates were incubated at
37 °C in 5 % CO2 for 72 h followed by assaying cell pro-
liferation using Cell Titer 96 non-radioactive cell prolif-
eration kit (Promega, USA). The percent inhibition of
cell proliferation was calculated for each concentration
of PLGA IL-1 ra or IL-1 ra and values were compared
across treatments. Data represents the average ± SD of
three independent experiments, each with duplicate
wells per group.
Biological activity of IL-1 ra released from PLGA IL-1 ra
microspheres using IL-1α stimulated bovine articular
cartilage explant model
Full-thickness bovine articular cartilage explants (12 mm
in diameter) were harvested from the femoral condyles
of skeletally mature steers with no signs of gross cartil-
age degeneration. Cartilage explants were maintained in
serum-free Dulbecco’s Modified Eagle Medium (DMEM;
Sigma Aldrich) supplemented with 1 % penicillin/
streptomycin. Cartilage explants were stimulated with
10 ng/ml of recombinant human IL-1α (R&D Systems)
with or without iron-oxide containing PLGA, PLGA IL-
1 ra at 20 ng/ml and 100 ng/ml (pooled from 4 different
preparations) or IL-1 ra at 20 ng/ml and 100 ng/ml (n =
6 in each group). Media collections and supplementation
with IL-1α and the drug were performed at 3, 5 and
7 days. Cumulative sulfated glycosaminoglycan (sGAG)
released over 7 days was measured using dimethyl-
methylene blue (DMMB) binding assay and compared
across groups (Mort & Roughley 2007).
Serum IL-1 ra levels following intra-articular
administration of PLGA IL-1 ra or IL-1 ra
A total of 50 μl of IL-1 ra (5 mg/ml) or 50 μl of PLGA
IL-1 ra (equivalent to 5 mg/ml of IL-1 ra) were adminis-
tered intra-articularly to naive male Lewis rats (8–10
weeks; n = 6 in each group) with an implanted jugular
vein catheter under isoflurane anesthesia. At 1, 3, 6,
12 and 24 h, blood was sampled via the jugular vein
catheter and serum IL-1 ra concentrations were deter-
mined using a commercially-available ELISA (Life
Technologies, USA).
ACLT in the rat
ACLT was performed in 8–10 weeks old male Lewis rats
(n = 42). Following anesthesia with intraperitoneal
Ketamine and Dexmedetomidine, the right knee joint
skin was shaved, disinfected with a topical antiseptic,
and a lateral skin incision was made to access the joint
capsule. A lateral incision was performed along the pa-
tellar tendon to open the capsule and expose the ACL.
Transecting the ACL was performed using a # 11 surgi-
cal blade and a positive anterior draw confirmed ACLT.
Closure of the capsule and skin was performed using
biodegradable sutures. All surgeries were performed by
author KE and all required approvals were obtained
from MCPHS University IACUC committee prior to the
commencement of the study. We have also utilized 4
control age-matched male Lewis rats.
Drug treatments
Following ACLT, animals were randomly assigned to the
following groups: PBS (n = 9), IL-1 ra (n = 13), PLGA IL-
1 ra (n = 14) and PLGA (n = 6). Animals received intra-
articular injections of PBS (50 μl), IL-1 ra (5 mg/ml;
50 μl), PLGA IL-1 ra (equivalent to 5 mg/ml of IL-1 ra;
50 μl; pooled from 4 different preparations) or empty
iron oxide-containing PLGA particles (100 mg/ml; 50 μl)
on days 7, 14, 21, and 28 following ACLT. Animals were
anesthetized with isoflurane and injections were per-
formed through the patellar tendon of the operated knee
joint.
Histological analyses and scoring
Animals were euthanized on day 35 following ACLT and
their ACLT joints were harvested. Following decalcifica-
tion, paraffin-embedded coronal sections were taken
through the weight-bearing areas of the ACLT joints of
each animal. Microtomed sections were collected every
250 μm and only the sections showing the tibial plat-
eaus, femoral condyles and the menisci were considered.
A total of 4 histological sections were stained with Safranin
O/Fast Green for assessment of cartilage integrity and 4 ad-
jacent histological sections were stained with Hematoxyln
and Eosin (H&E) for synovitis scoring. Cartilage histopath-
ology scoring was performed using a previously described
quantitative assessment tool (Pritzker et al. 2006). The
overall score is a product of the cartilage degeneration
grade and stage. Cartilage degeneration grade ranged from
0 indicating intact cartilage surface and morphology, nor-
mal architecture and proteoglycan staining and appropriate
chondrocyte orientation to 5 indicating cartilage denuda-
tion, full-thickness cartilage loss and formation of repair
tissue and underlying bone changes. The cartilage degener-
ation stage ranged from stage 1 involving <10 % of cartilage
surface/area to stage 4 involving > 50 % of cartilage surface/
area. Scoring was performed by two blinded investigators
and a consensus score was reported. Investigators scored
the medial and lateral sides of the 4 histological sections
and the overall joint score was the mean of the 8 scores.
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Synovial histopathology scoring was performed using the
criteria reported previously (Cake et al. 2008) and included
examination of intimal hyperplasia, inflammatory cell infil-
tration, subintimal fibrosis and vascularity with scores ran-
ging from 0 to 3 for each criterion and a range of aggregate
scores between 0 and 12.
Determination of urinary CTXII (uCTXII) levels in urines of
ACLT animals from different groups
On day 34 following ACLT, animals were housed in meta-
bolic cages and 24 h urine collection was performed.
Urine samples were centrifuged at 10,000 rpm and stored
at −20 °C until analysis. The uCTXII levels were quanti-
fied using the Urine Pre-Clinical Cartilaps ELISA (Immu-
nodiagnostic Systems, USA). Urinary creatinine was
measured colorimetrically using a commercially available
assay kit (Sigma Aldrich). The uCTXII levels were nor-
malized to urinary creatinine and expressed as μg per
nano moles of creatinine.
Statistical analyses
Percent IL-1 ra released from PLGA microspheres, per-
cent inhibition of lymphocyte proliferation, sGAG re-
lease, and IL-1 ra serum concentrations were plotted as
mean ± standard deviation (SD). Cartilage histopathology
scores, synovial pathology scores and uCTXII levels
were reported using box plots. Multiple group compari-
sons for variables that satisfy equal variance and normal-
ity assumptions were performed by one-way analysis of
variance (ANOVA) with Tukey’s post-hoc pairwise
comparisons. Variables that did not satisfy the two as-
sumptions were compared using ANOVA on the ranks.
Serum IL-1 ra concentrations following IL-1 ra or PLGA
IL-1 ra administrations were compared using Student’s
t-test. Statistical significance was set a priori at α = 0.05.
Results
PLGA IL-1 ra microsphere characterization and IL-1 ra
release
Representative scanning electron micrographs of PLGA
IL-1 ra is shown in Fig. 1a and b. Presence of iron oxide
is observed in the prepared particles. Additionally, particles
demonstrated some degree of size heterogeneity. The mean
effective diameter for PLGA particles was 1.9 ± 0.5 μm,
while the mean effective diameter of PLGA IL-1 ra parti-
cles was 5.1 ± 2.1 μm. The particle zeta potential of PLGA
IL-1 ra was found to be 5.44 ± 0.77 mV. The average per-
cent incorporation of IL-1 ra into iron-oxide containing
PLGA particles was 16.44 ± 3.96 %. The time-dependent
release of IL-1 ra from PLGA IL-1 ra is shown in Fig. 1c.
The percent of IL-1 ra content in the supernatant at 6 h
following reconstitution was 13.44 ± 9.27 % compared to
34.16 ± 12.04 %, 47.89 ± 12.71 %, 57.14 ± 11.71 %, and
93.90 ± 8.50 % at 12, 24, 48 and 72 h, respectively. Cumula-
tive IL-1 ra release at 72 h was significantly higher than cu-
mulative release at 6, 12, 24 and 48 h (p < 0.001).
Cumulative IL-1 ra release at 48 h was significantly higher
than cumulative release at 12 h (p < 0.001). Similarly, cu-
mulative IL-1 ra release at 24 h was significantly higher
than cumulative release at 6 h (p < 0.001).
Fig. 1 IL-1 ra containing PLGA microspheres. a, b Representative scanning electron micrographs of PLGA IL-1 ra microspheres at different magnifications.
c Release of IL-1ra from PLGA-IL1 ra microspheres over time. Cumulative IL-1 ra release at 72 h was significantly higher than cumulative release at 6, 12,
24 and 48 h. Similarly, cumulative IL-1 ra release at 24 and 48 h was significantly higher than cumulative release at 6 and 12 h, respectively. *p < 0.001. Data
represents the average ± SD of 4 different preparations
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Biological activity of IL-1 ra from PLGA IL-1 ra
The impact of PLGA encapsulation on inhibition of hu-
man lymphocyte proliferation by IL-1 ra is shown in
Fig. 2a. At the 1 ng/ml and 25 ng/ml concentrations, no
significant differences were found between PLGA IL-1
ra and IL-1 ra treatments. The percent inhibition of
lymphocyte proliferation following treatment with
25 ng/ml of PLGA IL-1 ra or IL-1 ra was significantly
higher than the percent inhibition of lymphocyte prolif-
eration following treatment with 1 ng/ml of PLGA IL-1
ra or IL-1 ra (p < 0.001). Treatment with PLGA particles
alone did not inhibit lymphocyte proliferation.
The impact of PLGA encapsulation on inhibition of
sGAG loss from bovine articular cartilage explants by
IL-1 ra is shown in Fig. 2b. IL-1α treatment resulted in a
significant increase in the cumulative release of sGAG
compared to untreated control (p < 0.001). Treatment
with PLGA particles alone did not alter sGAG release
from bovine explants. Treatment with PLGA IL-1 ra or
IL-1 ra at 20 ng/ml concentration resulted in a significant
reduction in sGAG release compared to IL-1α treatment
(p < 0.001). Additionally, 20 ng/ml IL-1 ra treatment re-
sulted in a significant reduction in sGAG release com-
pared to 20 ng/ml PLGA IL-1 ra treatment (p = 0.021). At
100 ng/ml, PLGA IL-1 ra and IL-1 ra treatments resulted
in a significant reduction in sGAG release compared to
IL-1α treatment (p < 0.001) with no difference between
cumulative sGAG release between PLGA IL-1 ra and IL-1
ra treatments.
IL-1 ra serum levels following intra-articular administration
of PLGA IL-1 ra or IL-1 ra
Serum IL-1 ra concentrations following intra-articular
administration of PLGA IL-1 ra or IL-1 ra is shown in
Fig. 3. At 1, 3 and 6 h, serum IL-1 ra levels were signifi-
cantly higher in the IL-1 ra group than the correspond-
ing levels in the PLGA IL-1 ra group (p < 0.001). At
12 h, there was no significant difference in serum IL-1
ra between PLGA IL-1 ra and IL-1 ra treatments. At
24 h, serum IL-1 ra levels in the PLGA IL-1 ra group
was significantly higher (p < 0.001) than the levels in the
IL-1 ra group.
Disease-modifying effect of PLGA IL-1 ra in rat ACLT
model
Cartilage histopathology scores of Safranin O-stained
specimens from the different experimental groups are
presented in Fig. 4a. PBS-treated ACLT cartilage exhibited
a significantly higher degree of cartilage degeneration
compared to non-surgical controls (p < 0.001). PLGA-
Fig. 2 Impact of PLGA incorporation on IL-1 ra biological activity. a Inhibition of interleukin-1 beta (IL-1β)-induced human lymphocyte proliferation by
IL-1 ra or PLGA-encapsulated IL-1 ra (PLGA IL-1 ra). The percent inhibition of lymphocyte proliferation following treatment with 25 ng/ml of IL-1 ra or
PLGA IL-1 ra was significantly higher than the percent inhibition of lymphocyte proliferation following treatment with 1 ng/ml of IL-1 ra or PLGA IL-1
ra. There was no significant difference in percent inhibition of lymphocyte proliferation between IL-1 ra and PLGA IL-1 ra treatments at 1 ng/ml or
25 ng/ml. *p < 0.001. Data represents the average ± SD of three independent experiments, each with duplicate wells per group. PLGA IL-1 ra was
pooled from 4 different preparations. b cumulative sulfated glycosaminoglycan (sGAG) release, over 7 days, from control bovine articular cartilage
explants (control), interleukin-1 α-stimulated (IL-1α), IL-1α stimulated + treatment with IL-1 ra at 20 ng/ml (IL-1 + IL-1 ra (20 ng/ml)), IL-1α
stimulated + treatment with PLGA IL-1 ra at 20 ng/ml (IL-1 + PLGA IL-1 ra (20 ng/ml)), IL-1α stimulated + treatment with IL-1 ra at 100 ng/ml
(IL-1 + IL-1 ra (100 ng/ml)) and IL-1α stimulated + treatment with PLGA IL-1 ra at 100 ng/ml (IL-1 + PLGA IL-1 ra (100 ng/ml)). (n = 6 in each
group). IL-1α treatment resulted in a significantly higher sGAG cartilage release compared to control. Treatment with IL-1 ra or PLGA IL-1 ra at
20 ng/ml resulted in a significant reduction in sGAG release compared to IL-1α alone. Similarly, treatment with IL-1 ra or PLGA Il-1 ra at 100 ng/ml
resulted in a significant reduction in sGAG release compared to IL-1 ra alone. There was no significant difference in sGAG release between IL-1 ra and
PLGA IL-1 ra at 20 ng/ml or 100 ng/ml. *p < 0.001. Data represents the average ± SD of 6 explants per group. PLGA IL-1 ra was pooled from 4
different preparations
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treated ACLT cartilage exhibited a comparable degree
of cartilage degeneration compared to PBS-treated
ACLT cartilage. IL-1 ra treatment did not significantly
reduce cartilage degeneration compared to PBS treat-
ment. On the contrary, PLGA IL-1 ra treatment signifi-
cantly reduced cartilage degeneration compared with
PBS or PLGA treatments (p < 0.001). There was no sig-
nificant difference in cartilage histopathology scores
between control and PLGA IL-1 ra groups.
Representative Safranin O and H&E stained histo-
logical sections are presented in Fig. 4b. Consistently,
PLGA IL-1 ra treatment resulted in cartilage tissue
architectural integrity, with some occasional fissures and
surface erosion that did not extend into the middle zone
as well as sGAG staining. On the contrary, PBS and
PLGA treatments displayed cartilage surface loss, loss of
sGAG staining and clefts, extending into the middle
zone. In animals treated with IL-1 ra, a significant vari-
ation in the extent of cartilage tissue degeneration was
observed. In some animals, IL-1 ra appeared to protect
the architecture of cartilage and prevent sGAG loss
while in other animals; IL-1 ra treatment did not prevent
cartilage degeneration.
Synovial histopathology scores of H&E stained sec-
tions from the different experimental groups are pre-
sented in Fig. 4c. PBS-treated ACLT synovia exhibited a
significantly higher degree of inflammation, hyperplasia
and cellular infiltration compared to non-surgical con-
trols (p < 0.001). PLGA IL-1 ra and IL-1 ra treatments
following ACLT significantly reduced synovial pathology
(p < 0.001) with no significant difference in the degree of
synovial pathology between the two treatments. PLGA
treatment alone had no disease modifying effect as the
extent of synovial pathology in PLGA-treated animals
was significantly higher than that in controls, PLGA IL-
1 ra or IL-1 ra treated animals (p < 0.001), and not signifi-
cantly different from PBS-treated animals. Representative
H&E stained synovia from the different experimental
groups is presented in Fig. 4d. PBS-treated ACLT syno-
vium demonstrated synovial hyperplasia and thickening
(as indicated by an arrow). This feature was also present
in PLGA-treated ACLT synovium and to a lesser extent in
IL-1 ra treated ACLT synovium. On the contrary, control
and PLGA IL-1 ra treated ACLT synovium displayed nor-
mal appearing synovium.
The normalized uCTXII epitopes released in urine
over a 24-h period from animals in the different experi-
mental groups are presented in Fig. 5. PBS-treated ACLT
animals demonstrated significantly higher uCTXII levels
compared to controls (p < 0.001). IL-1 ra treatment did
not significantly alter uCTXII levels compared to PBS
treatment. On the contrary, PLGA IL-1 ra treatment sig-
nificantly reduced uCTXII levels compared to PBS and
PLGA treatments (p < 0.001). PLGA treatment alone had
no disease modifying effect, as it did not significantly re-
duce uCTXII levels compared to PBS treatment.
Discussion
In this study, we have successfully demonstrated the feasi-
bility of encapsulating IL-1ra with superparamagnetic iron
oxide in biodegradable PLGA microspheres. The incorp-
oration of iron oxide allows the potential application of
magnetic targeting to enhance PLGA IL-1 ra microsphere
retention in arthritic joints (Butoescu et al. 2009a;
Butoescu et al. 2009b). Using IL-1 ra as the encapsulated
drug, a time-dependent release of IL-1 ra was observed
with more than 90 % of IL-1 ra released over 3 days. An
initial burst release of IL-1 ra, approximating one third of
the total IL-1 ra protein was observed at 12 h following re-
constitution. This initial burst is attributed to the porosity
of the microparticles and the hydrophilic nature of the
drug and not the degradation of the polymer (Lavi et al.
2007). Gorth et al. have shown that IL-1 ra can be success-
fully incorporated into PLGA microspheres. In their ex-
periment, an estimated 60 % of released IL-1 ra occurred
over the initial 3 days (Gorth et al. 2012). This difference
in cumulative IL-1 ra release may be attributed to a differ-
ence in PLGA IL-1 ra particle size with our preparation
having smaller particle sizes. One of the major challenges
to encapsulating protein drugs is protein destabilization
during preparation, storage and release processes (van de
Weert et al. 2000). We have successfully encapsulated IL-
1 ra with no loss to its bioactivity as demonstrated by the
ability of the IL-1 ra released from the microspheres to in-
hibit lymphocyte proliferation and prevent sGAG release
from cartilage explants to an extent similar to that of free
IL-1 ra.
The encapsulation of IL-1 ra in a PLGA polymer slows
the rate of IL-1 ra systemic clearance following intra-
Fig. 3 Serum IL-1 ra concentrations following intra-articular
administration of IL-1 ra or PLGA IL-1 ra. *p < 0.001. Data represents the
average ± SD of 6 animals in each experimental group
Elsaid et al. Journal of Experimental Orthopaedics  (2016) 3:18 Page 6 of 10
articular administration. Serum IL-1 ra concentrations
were consistently higher, approximating a 10-fold differ-
ence, up to 6 h following free IL-1 ra treatment com-
pared to PLGA encapsulated drug. This significant
difference is explained by the fact that the majority of
the drug remains encapsulated within the pharmaceut-
ical polymer and thus is unavailable for systemic absorp-
tion. This is in contrast to the free IL-1 ra where
a
c
b
Control PBS IL-1 ra
PLGA IL-1 ra PLGA
d
Control PBS IL-1 ra
PLGA IL-1 ra PLGA
Fig. 4 The disease-modifying activity of IL-1 ra or PLGA IL-1 ra in the rat ACLT model. a Cartilage histopathology scores of control joints and joints
undergoing ACLT and receiving weekly intra-articular injections of PBS (n = 9), IL-1 ra (n = 13), PLGA-encapsulated IL-1 ra (PLGA IL-1 ra; n = 14) or
PLGA microspheres (PLGA; n = 6) for 4 weeks starting one week following ACLT. PBS treated ACLT joints exhibited a significantly higher mean cartilage
histopathology score compared to control. Similarly, PLGA-treated ACLT joints exhibited a significantly higher mean cartilage histopathology score
compared to control. PLGA IL-1 ra treated ACLT joints demonstrated a significantly lower mean cartilage histopathology score compared to PBS or
PLGA-treated ACLT joints. *p < 0.001. Data represents average ± SD. b Representative Safranin O/Fast Green stained tibial plateau cartilage specimens
from control, ACLT animals receiving PBS, IL-1 ra, PLGA-IL1 ra or PLGA. ACLT joints exhibited loss of Safranin O staining indicative of glycosaminoglycan
loss, clefts extending into the middle zone and hypocellularity. PLGA IL-1ra treatment reduced glycosaminoglycan loss and the number and depth of
cartilage tissue fissures. Scale = 100 μm. c Synovial histopathology scores of control joints and joints undergoing ACLT and receiving weekly intra-
articular injections of PBS (n = 9), IL-1 ra (n = 13), PLGA IL-1 ra (n = 14) or PLGA (n = 6) for 4 weeks starting one week following ACLT. PBS treated ACLT
joints exhibited a significantly higher mean synovial histopathology score compared to control. Similarly, PLGA-treated ACLT joints exhibited a
significantly higher mean synovial histopathology score compared to control. IL-1 ra treated ACLT joints exhibited a significantly lower mean synovial
histopathology score compared to PBS or PLGA-treated ACLT joints. Similarly, PLGA Il-1 ra treated ACLT joints exhibited a significantly lower mean
synovial histopathology score compared to PBS or PLGA-treated ACLT joints. *p < 0.001. Data represents average ± SD. d Representative H&E-stained
synovia specimens from control, ACLT animals receiving PBS, IL-1 ra, PLGA IL-1 ra or PLGA. Arrows point to synovial hyperplasia evident in ACLT
animals treated with PBS, IL-1 ra and PLGA
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virtually all of the drug is in the synovial fluid and is
readily available for systemic absorption in a first-order
kinetic process. Interestingly, at 24 h following IA ad-
ministration, serum IL-1 ra concentrations in the PLGA
IL-1 ra treated animals were significantly higher than in
the free IL-1 ra treated animals. This difference can be
due to the release of IL-1 ra from the PLGA microparti-
cles and subsequent systemic absorption.
Using the rat ACLT model of PTOA, several of the
key pathological changes to cartilage and synovium has
been well documented (Caron et al. 1996; Elsaid et al.
2012; Jay et al. 2012; Elsaid et al. 2015). At 5 weeks fol-
lowing injury, cartilage surface roughness, reduced extra-
cellular matrix proteoglycan staining and emerging loss
of cartilage structural integrity, in the form of clefts,
have been consistently observed in all PBS-treated ani-
mals. Overall, treatment with free IL-1 ra did not lead to
a significant reduction in cartilage degeneration. While
in some animals IL-1 ra did show a chondroprotective
effect with preservation of cartilage matrix integrity, in
the majority of animals, IL-1 ra treatment failed to pro-
vide any disease-modifying effect. In contrast, PLGA IL-
1 ra treatment demonstrated a significant reduction in
cartilage degeneration and preservation of extracellular
matrix integrity. Across all IL-1 ra treatments, uCTXII
levels were reduced compared to PBS-treated animals.
uCTXII is a validated enzymatically-generated collagen
type II degradation biomarker (Christgau et al. 2001).
The reduction in uCTXII levels with IL-1 ra treatment
provides supporting evidence that early blockade of IL-1
α effects following a traumatic joint injury can slow
down the rate of cartilage degeneration.
Our understanding of the crosstalk between the syno-
vium and cartilage in the pathogenesis of OA is evolving.
Activation of toll-like receptors and the complement
cascade in the synovial lining by cartilage degradation
products plays a role in recruitment of inflammatory
cells, release of cytokines and chemokines leading to car-
tilage erosion and osteophyte formation (Scanzello et al.
2008; Scanzello & Goldring 2012; de Lange-Brokaar et
al. 2012). In the rat ACLT model, synovitis is evident at
5 weeks post-injury with significant inflammatory cell in-
filtration, increased vascularity and thickening of the
synovial lining. PLGA IL-1 ra treatment has resulted in a
significant reduction in synovial histopathology scores,
due to a reduction in inflammatory cell infiltration and
synovial thickening, compared to PBS treatment.
Taken together, our data suggests that encapsulating
IL-1 ra in a PLGA polymer is feasible with no deleteri-
ous impact on its biological activity and that this encap-
sulation delays IL-1 ra systemic clearance following
intra-articular administration. The delay in IL-1 ra sys-
temic absorption may be responsible for the disease-
modifying effect seen for PLGA IL-1 ra with prevention
of cartilage degeneration and reduction in synovitis. Our
future studies shall evaluate the impact of magnetic re-
tention on enhancing the existing disease-modifying
effect of intra-articular PLGA IL-1 ra, using a less fre-
quent dosing strategy.
A limitation of this study is the use of an immortalized
human lymphocyte cell line to evaluate the biological ac-
tivity of PLGA encapsulated IL-1 ra. Additionally, we
have not measured residual sGAG content in the bovine
cartilage explants and the impact of IL-1 ra encapsula-
tion on important and clinically relevant subchondral
bone changes evident in PTOA was not evaluated. In
the rat PTOA model, our IL-1 ra dosing strategy amelio-
rated synovitis but did not alter the extent of cartilage
degeneration. This may be attributed to the delayed on-
set of treatment at one week following the traumatic in-
sult compared with other reports that showed an effect
of IL-1 ra with immediate onset of treatment following
the insult (Caron et al. 1996; Elsaid et al. 2015; Furman
et al. 2014).
Conclusions
In summary, IL-1 ra is a promising pleiotropic disease-
modifying anti-PTOA drug whose use is limited by brief
joint residence time. We here in report on our success
in encapsulating IL-1 ra in an inert biocompatible PLGA
polymer that slowly degrades releasing the drug intra-
Fig. 5 Urinary CTXII (uCTXII) concentrations, normalized to urinary
creatinine level, collected over 24 h in control animals and animals
undergoing ACLT and receiving weekly intra-articular injections of
PBS (n = 7), IL-1 ra (n = 9), PLGA IL-1 ra (n = 9) or PLGA (n = 6) for
4 weeks starting one week following ACLT. PBS treated ACLT animals
exhibited a significantly higher mean uCTXII concentration compared
to control. Similarly, PLGA-treated ACLT animals exhibited a significantly
higher mean uCTXII concentration compared to control. PLGA IL-1
ra treated ACLT animals demonstrated a significantly lower mean
uCTXII concentration compared to PBS or PLGA-treated ACLT
animals. *p < 0.001. Data represents average ± SD
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articularly. This encapsulation has significantly improved
the efficacy of the drug in a rat model of PTOA and pro-
vided supporting evidence to the utility of formulating
IL-1 ra as a sustained release formulation for intra-
articular delivery.
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